Zimmer Biomet management check
ZBH · Health Care · Health Care Equipment · CEO Mr. Tornos
Filings as of
Closest peers in Health Care Equipment
- 153ISRGIntuitive Surgical72
- 158ABTAbbott Laboratories72
- 162SYKStryker Corporation71
- 185IDXXIdexx Laboratories69
- 199BSXBoston Scientific68
- 250RVTYRevvity64
- 284RMDResMed63
- 286GEHCGE HealthCare62
- 322STESteris60
- 353BDXBecton Dickinson58
The seven checks
- FlagTrailed its chosen peers
Have owners done well?
What $100 became since fiscal 2021
016thDetail
$100 invested at the start of fiscal 2021 grew to $63, against $127 for the peer group the company picked itself.
- WatchPay only loosely tracked returns
Does pay follow performance?
Pay actually paid $100 value, each on its own scale
5113thDetail
Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.02 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Watch2.3% of net income
What does the CEO cost owners?
$16.1m pay · $705.0m net income, FY2025
2025thDetail
$16.1m of reported pay in fiscal 2025, against $705.0m of net income.
- WatchInsiders are selling
Do they own the stock?
6 mo: ▲ $0 bought · ▼ $1.2m sold
——Detail
3 insiders sold $1.2m in the last six months and none bought.
- GoodShare count shrinking
Are owners being diluted?
Diluted shares −2.7% a year; flagged above +2%
Stock pay 1.1% of revenue
8375thDetail
Diluted shares changed -2.7% a year over the last three fiscal years. Stock-based pay was 1.1% of revenue in the latest year.
- Watch2 CEOs in the pay table
Is leadership stable?
9 filings under 8-K 5.02 in 3 years
CEOs: Bryan Hanson, Mr. Tornos
4018thDetail
CEOs in the pay table: Bryan Hanson, Mr. Tornos. 9 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- GoodNo red flags on file
Are the books clean?
Since 2021
- 0Restated
- 0Auditor changes
- 0Late filings
- 010-K amended
100100thDetail
No restatements, auditor changes or late filings since 2021.
Reading the scores
Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.
Hover a chart for its figures. Detail has the full reading.
Pay versus performance
From the proxy statement filed April 1, 2026.
Pay tied most to consolidated constant currency revenue
Other key measuresConsolidated constant currency revenueConsolidated free cash flowAdjusted operating profitAdjusted EPS growth
Show the figures
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | Mr. Tornos | $16.1m | $12.6m | $6.1m | $63 | $127 | $705.0m |
| 2024 | — | $15.0m | $9.2m | $3.9m | $73 | $117 | $903.8m |
| 2023 | Bryan Hanson | $12.8m | $10.3m | $5.0m | $83 | $106 | $1.0bn |
| 2022 | — | $16.4m | $20.5m | $4.7m | $87 | $97 | $231.4m |
| 2021 | — | $15.0m | $0 | $4.2m | $83 | $119 | $401.6m |
Insiders and the CEO's stakeSelling
3 insiders sold $1.2m in the last six months and none bought.
Open-market trades by officers and directors since May 21, 2026.
- SoldKevin R ThornalGrp Pres-Global Business$529kSep 11, 2026
- SoldSang YiGroup President, Asia Pacific$413kMay 29, 2026
- SoldChad F PhippsSee remarks below.$295kSep 4, 2026
Leadership and governance on file
All 11 filings
- Sep 8, 2026Leadership change8-K 5.02
- Apr 28, 2026Leadership change8-K 5.02
- Jan 12, 2026Leadership change8-K 5.02
- Jun 3, 2025Leadership change8-K 5.02
- May 27, 2025Leadership change8-K 5.02
- Feb 25, 2025Leadership change8-K 5.02
- Jun 20, 2024Leadership change8-K 5.02
- May 15, 2024Leadership change8-K 5.02
- Jan 5, 2024Leadership change8-K 5.02
- Aug 22, 2023Leadership change8-K 5.02
- May 16, 2022Leadership change8-K 5.02
Latest shareholder vote results: May 27, 2026, including the say-on-pay vote.
Where the money went
2021–2025: $3.2bn returned to owners in buybacks and dividends, 97% of net income, and $472.0m of pay in stock.
Show the figures
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $6.8bn | $6.9bn | $7.4bn | $7.7bn | $8.2bn |
| Net income | $401.6m | $231.4m | $1.0bn | $903.8m | $705.1m |
| Stock-based pay | $76.0m | $105.0m | $99.8m | $101.0m | $90.2m |
| Buybacks | — | $126.4m | $692.2m | $868.0m | $487.0m |
| Dividends | $200.1m | $201.2m | $200.9m | $196.0m | $190.3m |
| Diluted shares | 210m | 210m | 210m | 204m | 199m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.